New! Access the Toolkit on the Optimization of RAASi Therapyjbrown
Kidney diseases are intricately linked to increased morbidity with, and mortality from, other diseases and infections. An integrated approach to noncommunicable disease prevention and management that recognizes co-morbidities is critical to improving disease outcomes.
Since 2021, the ISN has collaborated with the American Society of Preventative Cardiology (ASP), the Heart Failure Association of the European Society of Cardiology (HFA), Kidney Disease Improving Global Outcomes (KDIGO), and the Renal Physicians Association (RPA) to co-create toolkits for advancing the prevention and management of cardio-renal complications.
The first topic selected by the group for such tools is the optimization of renin angiotensin aldosterone system inhibitors (RAASi) therapy and the management of related complications.
The toolkit presents helpful infographics serving as hands-on references for nephrologists, cardiologists, and other healthcare professionals involved in the multidisciplinary care of patients with cardio-renal complications.
Explore the toolkit to find educational and clinical infographics on:
- Nuts and bolts of RAASi therapy
- Management of hyperkalemia
- Dietary approaches to hyperkalemia
- Monitoring and managing acute changes in kidney function related to RAASi
- Talking to your patients about RAASi
The optimization of RAASi therapy toolkit is supported by an unrestricted educational grant from AstraZeneca and CSL Vifor.